RS61418B1 - Kompozicije glikopeptida - Google Patents

Kompozicije glikopeptida

Info

Publication number
RS61418B1
RS61418B1 RS20210108A RSP20210108A RS61418B1 RS 61418 B1 RS61418 B1 RS 61418B1 RS 20210108 A RS20210108 A RS 20210108A RS P20210108 A RSP20210108 A RS P20210108A RS 61418 B1 RS61418 B1 RS 61418B1
Authority
RS
Serbia
Prior art keywords
vancomycin
vol
molar ratio
lysine
alanine
Prior art date
Application number
RS20210108A
Other languages
English (en)
Serbian (sr)
Inventor
Ivona Jasprica
Sabina Keser
Katarina Pindric
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS61418(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of RS61418B1 publication Critical patent/RS61418B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
RS20210108A 2014-11-06 2015-11-06 Kompozicije glikopeptida RS61418B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076400P 2014-11-06 2014-11-06
US201562168749P 2015-05-30 2015-05-30
EP19174849.0A EP3542812B1 (en) 2014-11-06 2015-11-06 Glycopeptide compositions

Publications (1)

Publication Number Publication Date
RS61418B1 true RS61418B1 (sr) 2021-03-31

Family

ID=54478023

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20210108A RS61418B1 (sr) 2014-11-06 2015-11-06 Kompozicije glikopeptida
RS20200080A RS59851B1 (sr) 2014-11-06 2015-11-06 Kompozicije glikopeptida

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20200080A RS59851B1 (sr) 2014-11-06 2015-11-06 Kompozicije glikopeptida

Country Status (29)

Country Link
US (8) US10188697B2 (enExample)
EP (4) EP3542812B1 (enExample)
JP (2) JP6797795B2 (enExample)
KR (2) KR102603756B1 (enExample)
CN (1) CN107073072B (enExample)
AU (1) AU2015341763B2 (enExample)
BR (1) BR112017009405B1 (enExample)
CL (1) CL2017001139A1 (enExample)
CO (1) CO2017005391A2 (enExample)
CR (1) CR20170234A (enExample)
CY (2) CY1122960T1 (enExample)
DK (2) DK3542812T3 (enExample)
EA (1) EA035368B1 (enExample)
ES (2) ES2852550T3 (enExample)
HR (2) HRP20200101T1 (enExample)
HU (2) HUE049857T2 (enExample)
IL (1) IL252120B (enExample)
MX (1) MX387229B (enExample)
NZ (1) NZ731955A (enExample)
PH (1) PH12017500720A1 (enExample)
PL (2) PL3542812T3 (enExample)
PT (2) PT3542812T (enExample)
RS (2) RS61418B1 (enExample)
SA (1) SA517381446B1 (enExample)
SG (1) SG11201703568WA (enExample)
SI (2) SI3215173T1 (enExample)
TN (1) TN2017000182A1 (enExample)
WO (1) WO2016071495A1 (enExample)
ZA (1) ZA201702767B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015341763B2 (en) * 2014-11-06 2019-01-17 Hikma Pharmaceuticals Usa Inc. Glycopeptide compositions
WO2017111601A1 (en) * 2015-12-24 2017-06-29 Universiteit Leiden Composition and method for treating infections caused by vancomycin-resistant infectious agents in a subject
BR112018072948A2 (pt) * 2016-05-09 2019-02-19 Xellia Pharmaceuticals Aps composição farmacêutica líquida, e, método para a estabilização de um antibiótico glicopeptídeo em uma solução farmacêutica líquida.
EP3544616A4 (en) * 2016-11-23 2020-12-09 Gufic Biosciences Limited LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF DALBAVANCIN
JP7118412B2 (ja) * 2017-07-31 2022-08-16 東洋製薬化成株式会社 バンコマイシン懸濁液充填カプセル製剤
CN109725101B (zh) * 2017-10-31 2021-11-19 正大天晴药业集团股份有限公司 盐酸特拉万星原料中有关物质的检测方法
CN109078001B (zh) * 2018-09-21 2021-05-07 深圳浦瑞健康科技有限公司 一种万古霉素纳米脂质体组合物及其制备方法
US20220184173A1 (en) 2019-03-08 2022-06-16 Emphascience, Inc. Stable pharmaceutical formulations of peptide and protein drugs
US11433115B2 (en) * 2020-10-30 2022-09-06 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014969A1 (en) * 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
WO2022234036A1 (en) * 2021-05-07 2022-11-10 Xellia Pharmaceuticals Aps Oral liquid vancomycin formulations
CN115804832A (zh) * 2021-09-14 2023-03-17 海南普利制药股份有限公司 一种万古霉素水溶液组合物
WO2023171588A1 (ja) * 2022-03-08 2023-09-14 国立大学法人大阪大学 抗菌薬を含有するｐｌｇａ製剤
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
WO2024079223A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
EP4601616A1 (en) * 2022-10-12 2025-08-20 Hikma Pharmaceuticals USA Inc. Liquid dalbavancin composition
WO2025006267A1 (en) * 2023-06-26 2025-01-02 Venn Biosciences Corporation Peptide biomarkers for diagnosing primary sclerosing cholangitis or primary biliary cholangitis
GB202405996D0 (en) 2024-04-29 2024-06-12 Arecor Ltd Novel compositions
GB202405997D0 (en) 2024-04-29 2024-06-12 Arecor Ltd Novel compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
NZ270387A (en) 1994-01-28 1996-11-26 Lilly Co Eli Glycopeptide antibiotic, its production and compositions thereof
WO1997019690A1 (en) 1995-12-01 1997-06-05 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
US6800608B2 (en) 2001-06-22 2004-10-05 Beckman Coulter, Inc. Homogeneous assay of vancomycin using a stable particle-vancomycin conjugate, a novel rate enhancer, and a novel dose response modulator
CA2478470A1 (en) * 2002-03-26 2003-10-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Solubilization of weak bases
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
IL166157A0 (en) 2002-07-09 2006-01-15 Point Therapeutics Inc Methods and compositions relating to isoleucine boroproline compounds
CN1826129A (zh) * 2002-07-09 2006-08-30 尖端医疗有限公司 与异亮氨酸硼脯氨酸化合物相关的方法和组合物
ES2712656T3 (es) 2002-11-18 2019-05-14 Vicuron Pharmaceuticals Llc Métodos de administración de dalbavancina para el tratamiento de infecciones bacterianas
ES2482700T3 (es) 2005-02-14 2014-08-04 Venus Remedies Limited Terapia de combinación parenteral para enfermedades infecciosas causadas por una bacteria resistente a los medicamentos
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) * 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
WO2009075859A2 (en) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
JP2011080021A (ja) 2009-10-09 2011-04-21 Bridgestone Corp 熱可塑性エラストマー組成物及びその成形体
SG195038A1 (en) * 2011-05-19 2013-12-30 Savara Inc Dry powder vancomycin compositions and associated methods
WO2014026052A1 (en) 2012-08-08 2014-02-13 Vanderbilt University Composition with biofilm dispersal agents
RU2018135921A (ru) * 2012-11-29 2019-02-05 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9616098B2 (en) 2013-05-30 2017-04-11 Scidose, Llc Formulations of vancomycin
CN106573037A (zh) * 2014-03-14 2017-04-19 库蒂斯制药公司 用于万古霉素口服液的组合物和方法
AU2015341763B2 (en) * 2014-11-06 2019-01-17 Hikma Pharmaceuticals Usa Inc. Glycopeptide compositions
BR112018072948A2 (pt) 2016-05-09 2019-02-19 Xellia Pharmaceuticals Aps composição farmacêutica líquida, e, método para a estabilização de um antibiótico glicopeptídeo em uma solução farmacêutica líquida.
US11433115B2 (en) 2020-10-30 2022-09-06 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution

Also Published As

Publication number Publication date
US12161690B2 (en) 2024-12-10
US20220354927A1 (en) 2022-11-10
PT3542812T (pt) 2021-04-20
KR20230096142A (ko) 2023-06-29
WO2016071495A1 (en) 2016-05-12
RS59851B1 (sr) 2020-02-28
SI3215173T1 (sl) 2020-03-31
JP6797795B2 (ja) 2020-12-09
ES2769849T3 (es) 2020-06-29
US20250288640A1 (en) 2025-09-18
TN2017000182A1 (en) 2018-10-19
EP3834837A1 (en) 2021-06-16
CN107073072B (zh) 2021-06-18
HUE053347T2 (hu) 2021-06-28
US20170348385A1 (en) 2017-12-07
AU2015341763A1 (en) 2017-06-08
CY1124011T1 (el) 2022-05-27
MX2017005749A (es) 2018-01-11
ES2852550T3 (es) 2021-09-13
EP3215173B8 (en) 2020-03-11
EA035368B1 (ru) 2020-06-03
DK3542812T3 (da) 2021-04-12
JP7032488B2 (ja) 2022-03-08
HRP20210342T1 (hr) 2021-04-30
US11000567B2 (en) 2021-05-11
KR102763211B1 (ko) 2025-02-04
MX387229B (es) 2025-03-04
US10188697B2 (en) 2019-01-29
SG11201703568WA (en) 2017-05-30
US20210220433A1 (en) 2021-07-22
JP2017533218A (ja) 2017-11-09
KR102603756B1 (ko) 2023-11-16
CY1122960T1 (el) 2021-10-29
EP3215173A1 (en) 2017-09-13
CO2017005391A2 (es) 2017-10-31
JP2020183424A (ja) 2020-11-12
US10849956B2 (en) 2020-12-01
DK3215173T3 (da) 2020-03-23
EP4147710A1 (en) 2023-03-15
HUE049857T2 (hu) 2020-10-28
NZ731955A (en) 2023-07-28
EA201790997A1 (ru) 2017-09-29
IL252120A0 (en) 2017-07-31
HRP20210342T8 (hr) 2022-01-21
HRP20200101T1 (hr) 2020-04-03
ZA201702767B (en) 2018-12-19
PT3215173T (pt) 2020-04-03
BR112017009405B1 (pt) 2024-02-06
BR112017009405A2 (pt) 2018-01-02
EP3542812B1 (en) 2021-01-13
CL2017001139A1 (es) 2017-12-01
US11628200B2 (en) 2023-04-18
AU2015341763B2 (en) 2019-01-17
US20180133286A1 (en) 2018-05-17
CR20170234A (es) 2018-01-15
US10039804B2 (en) 2018-08-07
KR20170078830A (ko) 2017-07-07
CN107073072A (zh) 2017-08-18
IL252120B (en) 2020-07-30
PL3542812T3 (pl) 2021-07-12
US20230158101A1 (en) 2023-05-25
SA517381446B1 (ar) 2020-09-21
SI3542812T1 (sl) 2021-04-30
EP3542812A1 (en) 2019-09-25
CA2964524A1 (en) 2016-05-12
EP3215173B1 (en) 2020-01-01
US20200069768A1 (en) 2020-03-05
US11517609B2 (en) 2022-12-06
PH12017500720A1 (en) 2017-10-09
US20190160142A1 (en) 2019-05-30
PL3215173T3 (pl) 2020-05-18

Similar Documents

Publication Publication Date Title
US12161690B2 (en) Glycopeptide compositions
AU2017262943B2 (en) Stabilized glycopeptide antibiotic formulations
JP2025533238A (ja) 液体ダルババンシン組成物
CA2964524C (en) Glycopeptide compositions